Hansoh Pharma says Phase 3 ARTEMIS-008 study shows overall survival gain for risvutatug rezetecan in relapsed SCLC

• Hansoh Pharma presented interim Phase 3 ARTEMIS-008 results at the 2026 World Conference on Lung Cancer on Sept. 13, 2026.
• Risvutatug rezetecan (HS-20093) improved overall survival versus topotecan in relapsed small cell lung cancer, meeting the study’s primary endpoint.
• Outcome supports a move toward regulatory action in China, where the SCLC biologics license application has been accepted with priority review.
• GSK holds rights outside Greater China, positioning the asset for broader commercialization if regulators clear it.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 13, 2026, and is solely responsible for the information contained therein.